Referencia número: HY-10284

Copy Link Print Information

Linagliptin

(Synonyms: BI 1356)

15 Cited Publications

Revisión del cliente

Based on 15 publication(s) in Google Scholar

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC₅₀ of 1 nM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.74%
No. CAS: 668270-12-0
Fòrmula: C₂₅H₂₈N₈O₂
Peso molecular:472.54

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Linagliptin Chemical Structure

No. CAS: 668270-12-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (15)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Linagliptin is a highly potent, selective DPP-4 inhibitor with IC₅₀ of 1 nM.

IC₅₀ & Target

DPP-4

Ver todos los productos específicos de isoformas Dipeptidyl Peptidase :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	IC₅₀	1 nM Compound: 1, BI 1356	Inhibition of human DPP4 in Caco-2 cells by fluorescene assay Inhibition of human DPP4 in Caco-2 cells by fluorescene assay	[PMID: 18052023]
Caco-2	IC₅₀	1 nM Compound: B1 1356	Inhibition of DPP4 in human Caco-2 cells after 1 hr Inhibition of DPP4 in human Caco-2 cells after 1 hr	[PMID: 18485703]
Caco-2	IC₅₀	1 nM Compound: XV, Trajenta	Inhibition of DPP4 in human Caco2 cells using H-Ala-Pro-7-amido-4-trifluoromethylcoumarin as substrate after 1 hr by fluorescence assay Inhibition of DPP4 in human Caco2 cells using H-Ala-Pro-7-amido-4-trifluoromethylcoumarin as substrate after 1 hr by fluorescence assay	[PMID: 23623674]
CHO	IC₅₀	295 nM Compound: 1, BI 1356	Displacement of [N-methyl-3H]scopolamine from human recombinant muscarinic M1 receptor expressed in CHO cells Displacement of [N-methyl-3H]scopolamine from human recombinant muscarinic M1 receptor expressed in CHO cells	[PMID: 18052023]
HEK293	IC₅₀	>100 μM Compound: Linagliptin	Inhibition of OAT3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E-sul substrate uptake by liquid scintillation counting Inhibition of OAT3 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E-sul substrate uptake by liquid scintillation counting	[PMID: 23073734]
HEK293	IC₅₀	>100 μM Compound: Linagliptin	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E217betaG substrate uptake by liquid scintillation counting Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as reduction of [3H]E217betaG substrate uptake by liquid scintillation counting	[PMID: 23073734]
HEK293	IC₅₀	0.37 μM Compound: 2	Inhibition of recombinant mouse FAP purified from HEK293 cell supernatant using Ala-Pro-p-nitroanilide as substrate by spectrophotometry Inhibition of recombinant mouse FAP purified from HEK293 cell supernatant using Ala-Pro-p-nitroanilide as substrate by spectrophotometry	[PMID: 24617858]
HEK293	IC₅₀	0.37 μM Compound: 2,BI 1356, linagliptin, Tradjenta	Inhibition of mouse recombinant FAP expressed in HEK293 cells using Ala-Pro-p-nitroanilide as substrate incubated for 15 mins prior to substrate addition Inhibition of mouse recombinant FAP expressed in HEK293 cells using Ala-Pro-p-nitroanilide as substrate incubated for 15 mins prior to substrate addition	[PMID: 24900696]
HEK293	IC₅₀	41 μM Compound: Linagliptin	Inhibition of OCT1 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillation counting Inhibition of OCT1 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillation counting	[PMID: 23073734]
HEK293	IC₅₀	45 μM Compound: Linagliptin	Inhibition of OCT1 (unknown origin) expressed in HEK293 cells assessed as reduction of [ethyl 1-14C]TEA substrate uptake at 100 uM by liquid scintillation counting Inhibition of OCT1 (unknown origin) expressed in HEK293 cells assessed as reduction of [ethyl 1-14C]TEA substrate uptake at 100 uM by liquid scintillation counting	[PMID: 23073734]
HEK293	IC₅₀	80 μM Compound: Linagliptin	Inhibition of OCT2 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillation counting Inhibition of OCT2 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillation counting	[PMID: 23073734]
LLC-PK1	IC₅₀	66.1 μM Compound: Linagliptin	Inhibition of human P-glycoprotein expressed in pig LLC-PK1 cells assessed as reduction of [3H]digoxin substrate transport from basolateral to apical side by liquid scintillation counting Inhibition of human P-glycoprotein expressed in pig LLC-PK1 cells assessed as reduction of [3H]digoxin substrate transport from basolateral to apical side by liquid scintillation counting	[PMID: 23073734]

In Vitro

Linagliptin inhibits DPP-4 activity in vitro in several independent experiments with IC₅₀ values of 0.4, 0.5, 0.9, and 1.1 nM (mean IC₅₀, approximately 1 nM). Linagliptin inhibits FAP with an IC₅₀ of 89 nM (approximately 90-fold selectivity versus DPP-4)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In male Wistar rats, Beagle dogs, and Rhesus monkeys, xanthine linagliptin proves to be a highly efficacious, long-lasting, and potent DPP-4 inhibitor providing >70% inhibition for >7 h for all three species after oral administration of 1 mg/kg. Single oral administration of linagliptin to db/db mice 45 min prior to an oral glucose tolerance test reduced plasma glucose excursion in a dose-dependent manner from 0.1 mg/kg (15% inhibition) to 1 mg/kg (66% inhibition)^[1]. Linagliptin (3 and 10 mg/kg) dose-dependently inhibits the DPP-4 enzyme in plasma within 30 min of administration. Linagliptin (1 mg/kg, p.o.) significantly reduces glucose excursion by approximately 50%^[2]. Oral administration of the DPP-4 inhibitor linagliptin (3 mg/kg, p.o.) strongly reduces DPP-4 activity, stabilizes active GLP-1 in chronic wounds, and improves healing in ob/ob mice. At day 10 postwounding, linagliptin-treated ob/ob mice show largely epithelialized wounds characterized by the absence of neutrophils^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 668270-12-0
Appearance Solid
Peso molecular 472.54
Fòrmula C₂₅H₂₈N₈O₂
Color White to off-white
SMILES

O=C1N(C2=C(C(N1CC3=NC(C)=C4C=CC=CC4=N3)=O)N(CC#CC)C(N5CCC[C@@H](N)C5)=N2)C
Synonyms

BI 1356
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (15)

All Cell Proliferation/Viability AssayIHCIFIn Vivo Efficacy StudyFlow CytometryWB

Sort by:

Journal Impact Factor

J Clin Invest

Fatty acid transport protein-2 inhibition enhances glucose tolerance through α-cell-mediated GLP-1 secretion. [Abstract]

2025 Sep 16:e192011. PMID: 40956612
Adv Sci (Weinh)

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4-Targeted Probe. [Abstract]

2026 Jul;13(38):e16904. PMID: 41984505
Pharmacol Res

Targeted MSC therapy restores implantation by spatially reconstituting the RSPO1 niche via IL10-CXCL12 signaling. [Abstract]

2026 May 18:230:108249. PMID: 42155786
Neural Regen Res

Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease. [Abstract]

2023 Aug;18(8):1818-1826. PMID: 36751811

Linagliptin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1818-1826. [Abstract]

Immunohistochemical staining for TH in the SNpc and STR. The MPTP group showed weaker staining for TH than the CON group, while the MPTP + EX-4 and MPTP + Linagliptin (LINA, 5 mg/kg; i.c. at the back of the neck; once daily for 14 days) groups showed stronger staining for TH than the MPTP group. Scale bar: 200 µm, 40 µm for low and high magnification, respectively.

Linagliptin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1818-1826. [Abstract]

Immunofluorescence staining for the M2 phenotype microglia marker CD206 (red, Cy3) in the SN. The intensity of the CD206 signal is weaker in the MPTP group and stronger in the MPTP + EX-4 and MPTP + Linagliptin (LINA, 5 mg/kg; i.c. at the back of the neck; once daily for 14 days) groups. Scale bar: 50 µm, 20 µm for low and high magnification, respectively. The results showed that the number of anti-inflammatory M2 microglia was clearly reduced in the SN of mice in the MPTP group, whereas the number of anti-inflammatory M2 microglia was increased in the exendin-4 and linagliptin treatment groups.

Linagliptin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1818-1826. [Abstract]

The effect of Linagliptin (1 nM-1 µM; 30 min) on SH-SY5Y cell viability, as assessed by CCK-8.

Linagliptin purchased from MedChemExpress. Usage Cited in: Neural Regen Res. 2023 Aug;18(8):1818-1826. [Abstract]

Apoptosis of SH-SY5Y cells was detected by flow cytometry. There was an increase in early apoptosis in the MPP (+) group, and a decrease in the MPP (+) + EX-4 (100 nM; 24 h) and MPP (+) (3 mM; 24 h) + Linagliptin (LINA, 100 nM; 24 h) groups.
Cell Rep

Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells. [Abstract]

2023 Feb 28;42(2):112105. PMID: 36807138

Linagliptin purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Feb 28;42(2):112105. [Abstract]

DPP4 inhibitors (Linagliptin 200 nM, vildagliptin 300 nM) suppress the growth of THP1 cells (n = 3 wells).

Linagliptin purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Feb 28;42(2):112105. [Abstract]

Linagliptin (Lgp, 1 mg/kg; i.p.; once daily for 20 days) led to significantly increased survival of AML cell-transplanted mice due to slower AML development, similar to Ara-C treatment (100 mg/kg/day over 5 days).
Talanta

Simultaneous enantiomeric separation of linagliptin and clopidogrel by capillary electrophoresis for the individual, combined, and enantiomeric ecotoxicity evaluation on Pseudokirchneriella subcapitata. [Abstract]

2025 Mar 20:292:127992. PMID: 40132408
Biochem Pharmacol

Identification of a novel metabolite of vildagliptin in humans: Cysteine targets the nitrile moiety to form a thiazoline ring. [Abstract]

2018 Oct:156:312-321. PMID: 30172711
Int J Mol Sci

Acute and Chronic Exposure to Linagliptin, a Selective Inhibitor of Dipeptidyl Peptidase-4 (DPP-4), Has an Effect on Dopamine, Serotonin and Noradrenaline Level in the Striatum and Hippocampus of Rats. [Abstract]

2024 Mar 5;25(5):3008. PMID: 38474255
Neurochem Int

The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats. [Abstract]

2020 Feb;133:104616. PMID: 31809774
Molecules

Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal. [Abstract]

2022 Apr 12;27(8):2478. PMID: 35458676
Sci Rep

The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. [Abstract]

2017 Jun 28;7(1):4351. PMID: 28659588

Linagliptin purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Jun 28;7(1):4351. [Abstract]

Western blot analysis of CREB protein phosphorylation in pancreas of KKAy mice treated with HBK001 and Linagliptin (2 mg/kg; p.o.).
Toxicol Appl Pharmacol

Linagliptin ameliorates acetic acid-induced colitis via modulating AMPK/SIRT1/PGC-1α and JAK2/STAT3 signaling pathway in rats. [Abstract]

2022 Mar 1:438:115906. PMID: 35122774
BMC Pharmacol Toxicol

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. [Abstract]

2025 Dec 8;26(1):208. PMID: 41361888
bioRxiv

Fatty Acid Transport Protein-2 (FATP2) Inhibition Enhances Glucose Tolerance through α-Cell-mediated GLP-1 Secretion. [Abstract]

2025 Feb 6:2025.01.31.635976. PMID: 39975070
Research Square Preprint

2021 Oct.

Solvente y solubilidad

In Vitro:

DMSO : 25 mg/mL (52.91 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1162 mL

10.5811 mL

21.1622 mL

5 mM

0.4232 mL

2.1162 mL

4.2324 mL

10 mM

0.2116 mL

1.0581 mL

2.1162 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (10.58 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Kinase Assay^[3]

EDTA plasma (20 μL) is diluted with 30 μL of DPP-4 assay buffer (100 mM Tris and 100 mM NaCl, adjusted to pH 7.8 with HCl) and mixed with 50 μL of H-Ala-Pro-7-amido-4-trifluoromethylcoumarin. The 200 mM stock solution in dimethylformamide is diluted 1:1000 with water to yield a final concentration of 100 μM. The plate is incubated at room temperature for 10 min, and fluorescence in the wells is determined by using a Victor 1420 Multilabel Counter at an excitation wavelength of 405 nm and an emission wavelength of 535 nm. For the detection of DPP-4 activity in wound lysates, 100 μg of protein from the respective wound lysates are used instead of 20 μL of plasma. Active GLP-1 is also detected from 100 μg of respective wound tissue samples and analyzed by using the Mouse/Rat Total Active GLP-1 Assay Kit.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

A total of 4.0×10⁷ keratinocytes per well are seeded into 24-well plates. After reaching 50% confluence, cells are starved for 24 h with DMEM. Proliferation of cells is assessed by using 1 μCi/mL of [³H]methyl-thymidine in DMEM in the presence of 10% fetal bovine serum and increasing concentrations of linagliptin (3, 30, 300, or 600 nM) for 24 h. Cells are then washed twice with phosphate-buffered saline and incubated in 5% trichloroacetic acid at 4°C for 30 min, and the DNA is solubilized in 0.5mol/LNaOH for 30 min at 37°C. Finally, [³H]thymidine incorporation is determined.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Each experimental group (vehicle or linagliptin treatment) consists of 10 individual ob/ob mice (n=10). Animals are treated orally once a day (8:00 AM) by gastrogavage using vehicle (1% methylcellulose) or linagliptin (3 mg/kg body weight in 1% methylcellulose) beginning 2 days (day−2) before wounding. After wounding, animals are subsequently treated once a day throughout the 10-day healing period.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (280 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Eckhardt M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 d [Content Brief]

[2]. Thomas L, et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action [Content Brief]

[3]. Schurmann C, et al. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice. J Pharmacol Exp Ther. 2012 Jul;342(1):71-80. [Content Brief]

[4]. Huan Y, et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep. 2017 Jun 28;7(1):4351. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1162 mL	10.5811 mL	21.1622 mL	52.9056 mL
	5 mM	0.4232 mL	2.1162 mL	4.2324 mL	10.5811 mL
	10 mM	0.2116 mL	1.0581 mL	2.1162 mL	5.2906 mL
	15 mM	0.1411 mL	0.7054 mL	1.4108 mL	3.5270 mL
	20 mM	0.1058 mL	0.5291 mL	1.0581 mL	2.6453 mL
	25 mM	0.0846 mL	0.4232 mL	0.8465 mL	2.1162 mL
	30 mM	0.0705 mL	0.3527 mL	0.7054 mL	1.7635 mL
	40 mM	0.0529 mL	0.2645 mL	0.5291 mL	1.3226 mL
	50 mM	0.0423 mL	0.2116 mL	0.4232 mL	1.0581 mL

Keywords

Linagliptin

15 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Linagliptin

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Amino Acid Metabolism Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

RNA Binding Bioactive Compound Library

Alkyne Compound Library

Classic FDA-Approved Drug Library

Publications Citing Use of MedChemExpress (MCE) Linagliptin

Ver todos los productos específicos de isoformas Dipeptidyl Peptidase

Actividad biológica

Chemical Information

Publications (15)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Linagliptin Related Classifications

HY-10284 Related Classifications